Homologous Recombination Repair Alterations Do Not Modify the Prognostic Impact of Tumor Mutational Burden in Locally Advanced NSCLC Treated with Chemoradiotherapy and Durvalumab
IASLC WCLC 2026
F. Weinberg, Y. Taguchi, B. Rhead, J. Aredo, U. Jariwala, J. Mercer, J. Patel, J. Neal, K.M. Atkins, K.L. Reckamp, K. Sankar
Introduction
Concurrent chemoradiotherapy (CRT) followed by consolidation durvalumab is standard-of-care for unresectable stage III non-small cell lung cancer (NSCLC), yet outcomes remain heterogeneous. TMB is associated with improved immune checkpoint inhibitors (ICI) response, while homologous recombination repair (HRR) alterations are hypothesized to promote genomic instability and enhance tumor immunogenicity. However, the clinical relevance of HRR alterations in stage III NSCLC treated with CRT followed by durvalumab, and their relationship with TMB, remain unclear.
Methods
We conducted a retrospective cohort study using the Tempus Lens clinicogenomic de-identified database. Patients with NSCLC, available Tempus xT/xR (DNA/RNA) results, who underwent definitive CRT followed by durvalumab were included. Patients were stratified based on pathogenic alterations or homozygous deletions in 23 HRR genes. TMB was dichotomized as high (≥10 mut/Mb) or low. The primary endpoint was real-world overall survival (rwOS), defined as time from durvalumab start to death or loss to follow-up. Cox proportional hazards models adjusted for age, sex, race, smoking status, ECOG performance status, histology and PD-L1 expression.
Results
Of the 1,091 patients included (median age 69, 43% female, 39% adenocarcinoma), 19.9% harbored HRR alterations. HRR alteration was not associated with rwOS in univariable (HR 0.82, 95% CI: 0.60-1.10, p=0.18) or multivariable analyses (HR 0.84, 95% CI: 0.60-1.18, p=0.31). High TMB was independently associated with improved rwOS (HR 0.65, 95% CI: 0.50-0.84, p=0.001). Among HRR-altered tumors, high TMB was associated with improved rwOS (adjusted HR 0.47, 95% CI 0.22-1.00, p=0.049); similar benefit was observed in HRR-wildtype tumors (adjusted HR 0.61, 95% CI: 0.43-0.87, p=0.006). Among TMB-high tumors, HRR alterations were not associated with improved survival (adjusted HR 0.66, p=0.20); no association was observed in TMB-low tumors regardless of HRR status (adjusted HR 0.82, p=0.36). Other factors associated with improved rwOS included high PD-L1 expression and younger age; male sex, poor performance status, and squamous histology correlated with poorer rwOS (Table 1).
Conclusions
HRR alterations were not associated with survival in NSCLC patients treated with CRT and consolidation durvalumab. TMB was a robust and independent predictor of improved rwOS regardless of HRR status. These findings suggest that HRR alterations do not confer clinically meaningful immunogenicity beyond TMB. Their role as a prognostic biomarker in locally advanced NSCLC treated with consolidation ICI appears limited
Related publications